Evidence map›Paper›PMID 35203675›Full record

ArticleBiomedicines2022

Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson's Disease.

Dmitry Troshev, Dmitry Voronkov, Anastasia Pavlova, Denis Abaimov, Alexander Latanov, Tatiana Fedorova, Daniil Berezhnoy

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Gut-directed therapy in Parkinson's disease.Frontiers in pharmacology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Dmitry TroshevKoltzov Institute of Developmental Biology, Russian Academy of Sciences, Vavilov Street, 26, 119334 Moscow, Russia.ORCID 0000-0001-5948-9339
Dmitry VoronkovResearch Center of Neurology, Laboratory of Clinical and Experimental Neurochemistry, Volokolamskoeshosse, 80, 125367 Moscow, Russia.ORCID 0000-0001-5222-5322
Anastasia PavlovaBiological Faculty, Moscow State University, Leninskie Gory, 1s12, 119234 Moscow, Russia.
Denis AbaimovResearch Center of Neurology, Laboratory of Clinical and Experimental Neurochemistry, Volokolamskoeshosse, 80, 125367 Moscow, Russia.ORCID 0000-0001-6888-3223
Alexander LatanovBiological Faculty, Moscow State University, Leninskie Gory, 1s12, 119234 Moscow, Russia.ORCID 0000-0001-7388-3914
Tatiana FedorovaResearch Center of Neurology, Laboratory of Clinical and Experimental Neurochemistry, Volokolamskoeshosse, 80, 125367 Moscow, Russia.
Daniil BerezhnoyResearch Center of Neurology, Laboratory of Clinical and Experimental Neurochemistry, Volokolamskoeshosse, 80, 125367 Moscow, Russia.
Lomonosov Moscow State University · RUResearch Center of Neurology · RUKoltzov Institute of Developmental Biology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristics of the disease. One of such models, in which neuropathology is induced by chronic injections of low doses of mitochondrial toxin rotenone, is well established in rats. However, data on this model adapted to mice remain controversial. We have designed the study to describe the timecourse of motor and non-motor symptoms during chronic subcutaneous administration of rotenone (4 mg/kg daily for 35 days) in C57BL/6 mice. We characterize the underlying neuropathological processes (dopaminergic neuron degeneration, regional brain metabolism, monoamine neurotransmitter and lipid peroxidation changes) at different timepoints: 1 day, 2 weeks and 5 weeks of daily rotenone exposure. Based on the behavioral data, we can describe three stages of pathology: cognitive changes from week 2 of rotenone exposure, subtle motor changes in week 3-4 and motor dysfunction starting roughly from week 4. Neuropathological changes in this model include a general decrease in COX activity in different areas of the brain (acute effect of rotenone) and a more specific decrease in midbrain (chronic effect), followed by significant neurodegeneration in SNpc but not VTA by the 5th week of rotenone exposure. However, we were unable to find changes in the level of monoamine neurotransmitters neither in the striatum nor in the cortex, nor in the level of lipid peroxidation in the brainstem. Thus, the gradual progression of pathology in this model is linked with metabolic changes, rather than with oxidative stress or tonic neurotransmitter release levels. Overall, this study supports the idea that a low-dose rotenone mouse model can also reproduce different stages of PD as well as rats.

Indexed as

behaviorC57BL/6 micecatecholaminescytochrome-C oxidaselearningneurodegenerationParkinson’s disease modelrotenone

Identifiers

PMID35203675
PMCPMC8962442
OpenAlexW4213242506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.